Literature DB >> 30097508

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Nigel Russell1, Alan Burnett2, Robert Hills3, Sophie Betteridge3, Mike Dennis4, Jelena Jovanovic5, Richard Dillon5, David Grimwade5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30097508      PMCID： PMC6225356          DOI： 10.1182/blood-2018-05-851824

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Authors:  Uwe Platzbecker; Giuseppe Avvisati; Laura Cicconi; Christian Thiede; Francesca Paoloni; Marco Vignetti; Felicetto Ferrara; Mariadomenica Divona; Francesco Albano; Fabio Efficace; Paola Fazi; Marco Sborgia; Eros Di Bona; Massimo Breccia; Erika Borlenghi; Roberto Cairoli; Alessandro Rambaldi; Lorella Melillo; Giorgio La Nasa; Walter Fiedler; Peter Brossart; Bernd Hertenstein; Helmut R Salih; Mohammed Wattad; Michael Lübbert; Christian H Brandts; Mathias Hänel; Christoph Röllig; Norbert Schmitz; Hartmut Link; Chiara Frairia; Enrico Maria Pogliani; Claudio Fozza; Alfonso Maria D'Arco; Nicola Di Renzo; Agostino Cortelezzi; Francesco Fabbiano; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Sergio Amadori; Franco Mandelli; Gerhard Ehninger; Richard F Schlenk; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

2.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

3.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; David Bowen; Jonathan Kell; Steve Knapper; Yvonne G Morgan; Jennie Lok; Angela Grech; Gail Jones; Asim Khwaja; Lone Friis; Mary Frances McMullin; Ann Hunter; Richard E Clark; David Grimwade
Journal:  Lancet Oncol       Date:  2015-09-14       Impact factor: 41.316

Review 5.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

6.  Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.

Authors:  A K Burnett; R K Hills; D Grimwade; J V Jovanovic; J Craig; M F McMullin; J Kell; K Wheatley; J A L Yin; A Hunter; D Milligan; N H Russell
Journal:  Leukemia       Date:  2012-12-10       Impact factor: 11.528

7.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245
  7 in total
  14 in total

Review 1.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 2.  Treatment for relapsed acute promyelocytic leukemia.

Authors:  Masamitsu Yanada
Journal:  Ann Hematol       Date:  2022-08-16       Impact factor: 4.030

Review 3.  Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?

Authors:  Felicetto Ferrara; Alessandra Picardi
Journal:  Cancers (Basel)       Date:  2019-12-24       Impact factor: 6.639

4.  UK Experience of an Alternative ATO Dosing Regimen in APL.

Authors:  Nigel Russell; Richard Dillon
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

Review 5.  Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia.

Authors:  Uday Kulkarni; Vikram Mathews
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 6.  Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.

Authors:  Marike W van Gisbergen; Emma Zwilling; Ludwig J Dubois
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

7.  Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach.

Authors:  Matteo Molica; Carla Mazzone; Tiziana Ottone; Pasquale Niscola; Elisabetta Abruzzese; Stefano Fratoni; Maria Teresa Voso; Paolo de Fabritiis
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

Review 8.  Acute myeloid leukemia: current progress and future directions.

Authors:  Hagop Kantarjian; Tapan Kadia; Courtney DiNardo; Naval Daver; Gautam Borthakur; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2021-02-22       Impact factor: 11.037

9.  The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia.

Authors:  Vinh Thanh Tran; Thang Thanh Phan; Hong-Phuoc Mac; Tung Thanh Tran; Toan Trong Ho; Suong Phuoc Pho; Van-Anh Ngoc Nguyen; Truc-My Vo; Hue Thi Nguyen; Thao Thi Le; Tin Huu Vo; Son Truong Nguyen
Journal:  BMC Res Notes       Date:  2020-08-26

10.  Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.

Authors:  Emiliano Fabiani; Laura Cicconi; Anna Maria Nardozza; Antonio Cristiano; Marianna Rossi; Tiziana Ottone; Giulia Falconi; Mariadomenica Divona; Anna Maria Testi; Ombretta Annibali; Roberto Castelli; Vladimir Lazarevic; Eduardo Rego; Pau Montesinos; Jordi Esteve; Adriano Venditti; Matteo Della Porta; William Arcese; Francesco Lo-Coco; Maria Teresa Voso
Journal:  Cancer Med       Date:  2021-05-27       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.